| Top 5 Stories : |
|
Tomorrow’s Selling Strategies: Invest & Test
Faced with a changing commercial marketplace, pharmaceutical leaders are investing heavily in new but largely unproven selling strategies—and they will continue doing so even though many of these new approaches are producing mixed results.
Read more
|
|
|
|
Sponsored
learn more about how to leverage Data and Analytics to enhance Copay Program Performance with this White Paper and Case Study.
 Read more
|
|
Can Payers and Drug Industry Agree on Real Value?
Recent developments in the pharmaceutical industry give the strong impression that both payers and industry are struggling to understand what represents “value” to our customers. The epicenter of many value discussions has been the United Kingdom, where three years of intensive discussions have sought to quantify the value of prescription drugs through Value-Based Pricing (VBP).
Read more
|
|
|
Accelerated Change: Understanding the FDA’s Expedited Pathways
Patients want access to medicines sooner. A 2012 Quintiles survey of patients living with a chronic disease found that those with the greatest unmet health need are willing to accept more uncertainty about new therapies provided these therapies offer some potential to improve their health.
Read more
|
|
|
Personalized Medicine at a Crossroads
With so much discussion around personalized medicine in recent years, it is easy to forget that we are still in the infancy of this new era. Indeed, no universally agreed definition of personalized or precision medicine even exists (instead we have numerous often contradictory versions).
Read more
|
|
